United Kingdom · Question · Written question
UIN 74757
Thyroid Cancer: Liothyronine
Introduced
3 September 2025
Last action
9 October 2025 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
9 October 2025
Summary
To ask the Secretary of State for Health and Social Care, when NICE last reviewed its guidance on the (a) availability and (b) prescribing of T3 for the treatment of thyroid cancer; and whether he has plans to improve access to T3 for patients where it is
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
3 September 2025
Written question
To ask the Secretary of State for Health and Social Care, when NICE last reviewed its guidance on the (a) availability and (b) prescribing of T3 for the treatment of thyroid cancer; and whether he has plans to improve access to T3 for patients where it is
Source: Commons
9 October 2025
Answer
The National Institute for Health and Care Excellence (NICE) has not made any recommendations on the use of liothyronine in the treatment of thyroid cancer. NICE published a guideline on the assessment and management of thyroid cancer in December 2022. Th...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-09-03/74757
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1831901
- uk · wq-1831901 · source updated 9 October 2025